Acquired MYC rearrangement potentially associated with ibrutinib resistance in mantle cell lymphoma
{{output}}
Mantle cell lymphoma (MCL) is a subtype of mature B-cell lymphoma characterized by the expression of CD5, cyclin D1, and SOX11, along with the IGH::CCND1 rearrangement. While the introduction of ibrutinib, a Bruton tyrosine kinase inhibitor, has significantly ... ...
